Patients with advanced solid tumors, lymphomas, or myeloma may be eligible for NCI-MATCH, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment.
The trial is for cancer patients who meet all of the following pre-qualifications:
To find patients who may be eligible for this trial, several commercial and academic laboratories are permitted by the National Cancer Institute to identify and refer potentially eligible patients to the trial based upon their standard tumor gene tests ordered by physicians to guide clinical care for their patients. Tumor gene testing by a designated lab is the only pathway for new patients to enroll into the trial. This process applies to any cancer patient who gets tumor gene testing at one of the nearly 1100 clinical sites participating in the trial.
For more information, visit the Genomic Testing section.
Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.